Finally, the sensitivity of mesenchymal NSCLC cells to Plk1 inhibition is linked to cMet phosphorylation via the vimentin and β1‐integrin pathway (a ligand‐independent and understudied pathway), leading to cMet activation in NSCLC. Here, MET is linked to non-small cell lung carcinoma.